Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

NCT05065216 is registered in ClinicalTrials.gov with DiaMedica Therapeutics Inc as lead sponsor.

NCT NCT05065216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05065216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Lead sponsor
DiaMedica Therapeutics Inc
Phase
Phase 2/3
Overall status
Recruiting
Start date
November 7, 2021
Completion date
December 31, 2026
Enrollment
728 (estimated)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

acute stroke, ischemic stroke, stroke